The brand drug lobbies dropped Thursday (June 28) their lawsuit against Nevada’s insulin-price transparency law. The Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization sued Nevada in September 2017 over the law, which forces drug makers to disclose pricing information when insulin product prices rise faster than medical inflation. PhRMA and BIO claimed the state law was preempted by federal trade secrets law, was an unconstitutional taking and violated the Commerce Clause. The drug industry’s claims that...